Members of the Board and executives enter agreements of subscription commitment in the rights issue
Phase Holographic Imaging PHI AB ("PHI") hereby announces that the company has received additional subscription commitments of approximately 3.8 MSEK from the Chairman of the Board, Klas Cramborn, Board members Linda Neckmar and Jan Richardsson, CEO Peter Egelberg and deputy Ann Christine Egelberg among others. Together with earlier announced subscription commitments, PHI has in total received subscription commitments of approximately 8.4 MSEK. No compensation is paid for the subscription commitments.
Since previously, PHI has agreed subscription guarantees of approximately 24.2 MSEK. In total, the company has thus in advance, by agreement, secured approximately 32.7 MSEK (71 %) of the rights issue which begins tomorrow, June 28, and which continues until July 17, 2018.
In addition to the previously signed subscription commitments, PHI now has agreed on subscription commitments with the following parties.
|Name||Subscription commitment (SEK)|
|Cratburn Superaunnation Fund A/C||761,623.80|
|Skymar Superaunnation Fund A/C||594,904.80|
|Ann Christine Egelberg||199,920.00|
|Löddeköpinge Plantskola AB||198,277.80|
|Västra Sund Invest AB (Jan Richardsson)||66,616.20|
Sedermera Fondkommission is the financial advisor to PHI in connection to the rights issue.
This information is information that Phase Holographic Imaging is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on June 27, 2018.
Phase Holographic Imaging (PHI) leads the ground-breaking development of time-lapse cytometry instrumentation and software. With the first instrument introduced in 2011, the company today offers a range of products for long-term quantitative analysis of living cell dynamics that circumvent the drawbacks of traditional methods requiring toxic stains. Headquartered in Lund, Sweden, PHI trades through a network of international distributors. Committed to promoting the science and practice of time-lapse cytometry, PHI is actively expanding its customer base and scientific collaborations in cancer research, inflammatory and autoimmune diseases, stem cell biology, gene therapy, regenerative medicine and toxicological studies.